Detection and treatment of conditions characterized by perfusion shortage
AssigneeFalcon BioScience, LLC
InventorHenricus J. DUCKERS
Life of this patent
Estimating the term…
Abstract
Methods of detecting a condition comprising neoangiogenesis, ischemia, or both, or risk thereof in a subject. Methods of inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, or preventing a condition comprising perfusion shortage (such as neoangiogenesis, ischemia, or both) in a subject in need thereof are described. Kits are described.
Claims28
A method for analyzing a biological sample, comprising:
- (a) receiving the biological sample from a subject;
- (b) wherein when the subject is a female subject, assaying expression levels of two or more genes from a female targeted set of genes to generate an output comprising the expression levels from (b) indicative of the female subject's having a condition selected from ischemic cardiovascular disease, ischemic heart disease, coronary artery disease, cardiovascular congenital disease, hypertrophic or dilating cardiomyopathy, heart failure;
- (c) wherein when the subject is a male subject, assaying expression levels of two or more genes from a male targeted set of genes to generate an output comprising the expression levels from (c) indicative of the male subject's having a condition selected from ischemic cardiovascular disease, ischemic heart disease, coronary artery disease, cardiovascular congenital disease, hypertrophic or dilating cardiomyopathy, heart failure;
- and
- (d) providing a treatment to the subject, the treatment selected from the group consisting of beta-blockers, calcium channels antagonists, nitrates, aspirin, cholesterol-lowering compounds, angiotensin converting enzyme (ACE) inhibitors, and ranolazine.
2-4. (canceled)
6-7. (canceled)
(canceled)
12-13. (canceled)
15-18. (canceled)
A method for analyzing a biological sample obtained from a subject, comprising:
- (i) subjecting a plurality of hematopoietic endothelial precursor cells (EPCs), fractions of the plurality of hematopoietic EPCs, secretions of the plurality of hematopoietic EPCs, or any combination thereof isolated from the biological sample, to a gene expression analysis, wherein the gene expression analysis comprises assaying expression levels of two or more genes from a plurality of identified genes;
- (ii) generating an output comprising the gene expression levels, wherein the gene expression levels are indicative of the subject having a condition selected from ischemic cardiovascular disease, ischemic heart disease, coronary artery disease, cardiovascular congenital disease, hypertrophic or dilating cardiomyopathy, heart failure;
- and
- (iii) providing a treatment to the subject, the treatment selected from the group consisting of beta-blockers, calcium channels antagonists, nitrates, aspirin, cholesterol-lowering compounds, angiotensin converting enzyme (ACE) inhibitors, and ranolazine.
21-24. (canceled)
26-27. (canceled)
29-67. (canceled)
Dependencies are inferred from the claim text.